Literature DB >> 11498789

Expression of truncated FHIT transcripts in cervical cancers and in normal human cells.

C P Matthews1, K Shera, N Kiviat, J K McDougall.   

Abstract

To analyse FHIT transcription patterns in cervical cancer, a series of primary cervical tumors and normal control samples were studied using RT-PCR. Full length and truncated FHIT transcripts were detectable in all samples tested. Interestingly, the expression of truncated FHIT transcripts by primary epithelial cells in vitro was associated with confluency. The breakpoints of most transcript deletions coincided with genuine splice site sequences, suggesting that they resulted from alternative splicing. These findings demonstrate that truncated FHIT transcripts are commonly detected in both normal and tumor tissues, and suggest that these altered transcripts are not causally related to tumorigenesis in cervical cancer.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11498789     DOI: 10.1038/sj.onc.1204622

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  4 in total

Review 1.  Alpha T-catenin (CTNNA3): a gene in the hand is worth two in the nest.

Authors:  James D Smith; Maria H Meehan; John Crean; Amanda McCann
Journal:  Cell Mol Life Sci       Date:  2011-05-20       Impact factor: 9.261

2.  Restoration of fragile histidine triad (FHIT) expression induces apoptosis and suppresses tumorigenicity in lung and cervical cancer cell lines.

Authors:  Luca Roz; Marcella Gramegna; Hideshi Ishii; Carlo M Croce; Gabriella Sozzi
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-12       Impact factor: 11.205

3.  Re-splicing of mature mRNA in cancer cells promotes activation of distant weak alternative splice sites.

Authors:  Toshiki Kameyama; Hitoshi Suzuki; Akila Mayeda
Journal:  Nucleic Acids Res       Date:  2012-06-06       Impact factor: 16.971

4.  A novel approach to simultaneously scan genes at fragile sites.

Authors:  Pascale Willem; Jacqueline Brown; Jan Schouten
Journal:  BMC Cancer       Date:  2006-08-08       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.